Discordance between non-HDL cholesterol and LDL cholesterol levels in patients with diabetes without previous cardiovascular events;Discordance entre les concentrations de cholestérol non HDL et de cholestérol LDL chez des patients diabétiques indemnes d'antécédents cardiovasculaires

Diabetes and Metabolism

Volumn 36, Issue 4, 2010, Pages 299-304

  Idris, I ^a,b   Al Ubaidi, F ^a  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes; Discordance; Non HDL cholesterol; Residual risk

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PREVALENCE; PRIMARY MEDICAL CARE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; GREAT BRITAIN; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 77956947289     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.02.002     Document Type: Article

References (24)

1. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R et al. Cholesterol Treatment Trialists' (CTT). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
2. Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 2005, 96(7):3K-13K.
3. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008, 5:319-335. Residual Risk Reduction Initiative (R3I).
4. Cromwell W.C., Otvos J.D. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol<100mg/dl. Am J Cardiol 2006, 98(15):1599-1602.
5. Otvos J.D., Jeyarajah E.J., Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90(17):22i-29i.
6. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996, 42(4):515-523.
7. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. Atorvastatin Comparative Cholesterol Efficacy and Safety study correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001, 88:265-269. ACCESS Study Group.
8. Cui Y., Blumenthal R.S., Flaws J.A., Whiteman M.K., Langenberg P., Bachorik P.S., et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161:1413-1419.
9. Lu W., Resnick H.E., Jablonski K.A., Jones K.L., Jain A.K., Howard W.J., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23.
10. Kastelein J.J., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117:3002-3009.
11. Leroux G., Lemieux I., Lamarche B., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels Metabolism. 2000, 49:53-61.
12. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
13. Burke A., Dattani H., Robinson M. Feasibility study and methodology to create a Quality Evaluated Database of Primary Care Data. Inform Prim Care 2004.
14. Lewis J.D., Schinnar R., Bilker W.B., Wang X., Strom B.L. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2006, 25. [Epub ahead of print].
15. Charlton-Menys V., Betteridge D.J., Colhoun H., Fuller J., France M., Hitman G.A., et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009, 55:473-480.
16. Wägner A.M., Sánchez-Quesada J.L., Pérez A., Rigla M., Cortés M., Blanco-Vaca F., Ordóñez-Llanos J. Inaccuracy of calculated LDL-cholesterol in type 2 diabetes: consequences for patient risk classification and therapeutic decisions. Clin Chem 2000, 46:1830-1832.
17. Kathiresan S., Otvos J.D., Sullivan L.M., Keyes M.J., Schaefer E.J., Wilson P.W., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113:20-29.
18. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance Diabetes 2003, 52:453-462.
19. Wägner A.M., Pérez A., Calvo F., Bonet R., Castellví A., Ordóñez J. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999, 22:812-817.
20. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
21. Pedersen T.R., Olsson A.G., Faergeman O., Kjekshus J., Wedel H., Berg K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460.
22. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., Stewart R.A., et al. LIPID Study Investigators Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 2002, 105:1162-1169.
23. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000, 20:2408-2413.
24. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591. VA-HIT Study Group.